Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Shorts Strengthened By 0.53%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Corporate Logo

Change of 0.53% for Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI)’s short interest was reported. FINRA announced short interest of BCLI’s total 1.13 million shares. That’s 0.53% up from 1.13 million shares. With Average volume 38,500, BCLI’s former position will take 29 days to restore. Brainstorm Cell Therapeutics Inc’s short interest float is 7.05%.

The stock decreased 2.72% or $0.1 during the last trading session, hitting $3.57.Currently Brainstorm Cell Therapeutics Inc. is downtrending after 25.37% change in last February 2, 2018. BCLI has also 43,866 shares volume. The stock underperformed the S&P500 by 25.37%.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others.The company has $73.93 million market cap. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd.Last it reported negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

For more Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news posted recently go to: Seekingalpha.com, Globenewswire.com, Globenewswire.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Brainstorm files IND for mid-stage study of NurOwn in progressive MS – Seeking Alpha” posted on November 19, 2018, “BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy Platform – GlobeNewswire” on September 12, 2018, “BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week – GlobeNewswire” with a publish date: January 03, 2019, “BrainStorm granted Japanese Patent for Nurown – Seeking Alpha” and the last “Health Care Sector Update for 12/17/2018: PTI, EVFM, BCLI, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” with publication date: December 17, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.